logo
Plus   Neg
Share
Email

Pre-market Movers For Dec 7 (NFLX, ACRX, AMRN, AVGO, ZGNX)

Gainers:

AcelRx Pharmaceuticals, Inc. (ACRX) is rising 5 percent to $3.48. The company announced that it has priced its underwritten public offering of 12.5 million common shares at $3.31 per share.

Decliners:

Netflix, Inc. (NFLX) is down 0.36 percent to $85.86. Netflix disclosed that the company and its chief executive Reed Hastings each received a Wells Notice from SEC Staff about its intent to recommend to the SEC to bring a civil action for violations of fair disclosure related to statement he posted in Facebook in July about the 1 billion hour service usage.

Amarin Corporation plc (AMRN) is plunging 19 percent to $9.71. The company announced $100 million non-equity financing through a hybrid debt-like instrument. The company also noted that it is continuing to assess strategic options.

Avago Technologies Ltd. (AVGO) is falling over 2 percent to $34.30. The company announced the sale of 21.49 million ordinary shares by certain existing shareholders, including its President and chief executive and entities affiliated with certain directors.

Trading halt:

Trading in shares of Zogenix, Inc. (ZGNX) was halted.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT